After months of mounting pressure amid lurid allegations, OrbiMed’s Isaly steps down


Sam Isaly has now finally left OrbiMed, the venture capital firm he founded, amid allegations of sexual impropriety. 

Not, of course, that you would know that from OrbiMed’s rather short PR, which calls his departure “part of ongoing succession planning,” with no mention of why he is leaving, or the allegations (something it has form in).

Its statement reads: “Samuel D. Isaly has transferred his controlling interest in OrbiMed and, as a result, is stepping down from his position as Managing Member of the firm. The terms of the transfer were not disclosed.

Free Daily Newsletter

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The firm’s five other Partners, Sven H. Borho, Carl L. Gordon, Jonathan T. Silverstein, W. Carter Neild and Geoffrey C. Hsu, will continue their ownership of the firm. Effective immediately, the Managing Member role has been transferred to Mr. Borho, Mr. Gordon and Mr. Silverstein.

“Mr. Isaly intends to continue to practice his investment skills as the Chief Investment Officer of the Isaly Family Office, and in other future activities, subject to his obligations to OrbiMed. Mr. Isaly thanks all of his colleagues and friends for their continued support and looks forward to many more years of investing excellence.”

It seemed as if Isaly was on the verge of leaving back in December, coming after Damian Garde for the healthcare and biopharma news site STAT reported allegations from five women who claimed that between 2000 and 2015, Isaly had “regularly sexually harassed OrbiMed’s female employees, particularly executive assistants.”

Two of the former employees said he repeatedly exposed female colleagues to pornography in the office. One said Isaly played a “prank on her with a sex toy.”

Isaly has denied the allegations, and OrbiMed issued a statement last year when they first surfaced, saying it “takes gender equality seriously and wishes to encourage a supportive work environment and equal opportunity for all employees.”

STAT, after this denial, reported an on-the-record account of his alleged behavior from Yanping Ren, who worked part-time at OrbiMed for 18 months as an intern, who said Isaly routinely made “vulgar and demeaning remarks to women in the workplace, including commenting on their bodies.”

“It was so normal in the company,” Ren told Garde. “It was like a fact of life that everyone had to accept. Sam just did what he could get away with.”

OrbiMed then issued a statement in early December, saying that Isaly was now to “step down … pursuant to years-long succession planning discussions” but did not mention or allude to the allegations against him.

It seems, however, that he hung around for more than four months, with a story by STAT over the weekend saying his actual departure now comes after “months of internal strife at OrbiMed,” according to people familiar with the matter, speaking anonymously to Garde.

The people claimed that Isaly “dragged his feet in the process” and accused him of “unilaterally approving the press release that announced his retirement without the approval of the other partners.”

Source link


Please enter your comment!
Please enter your name here